Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 36

Clinical Success at PTE by Baseline Pathogen* (OPTIC) Highly Effective Across Key Gram (+), Gram (–) & Atypical CABP Pathogens Omadacycline (N=204) Moxifloxacin (N=182) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Atypical Pathogens 118 109 ( 92.4) 106 97 ( 91.5) Mycoplasma pneumoniae 70 66 ( 94.3) 57 50 ( 87.7) Chlamydophila pneumoniae 28 25 ( 89.3) 28 25 ( 89.3) Legionella pneumophila 37 35 ( 94.6) 37 36 ( 97.3) Gram-Negative Bacteria (aerobes) 79 67 ( 84.8) 68 55 ( 80.9) Haemophilus influenzae 32 26 ( 81.3) 16 16 (100.0) Haemophilus parainfluenzae 18 15 ( 83.3) 17 13 ( 76.5) Klebsiella pneumoniae 13 10 ( 76.9) 13 11 ( 84.6) Gram-Positive Bacteria (aerobes) 61 52 ( 85.2) 56 49 ( 87.5) Streptococcus pneumoniae 43 37 ( 86.0) 34 31 ( 91.2) PSSP 26 23 ( 88.5) 22 21 ( 95.5) Macrolide Resistant 10 10 (100.0) 5 5 (100.0) Staphylococcus aureus 11 8 ( 72.7) 11 9 ( 81.8) *10 or More Isolates for Omadacycline